News
Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback